High R&D spending and a high rate of failure of drugs in clinical trials have led pharmaceutical companies to look for ways to make more reliable stop/go decisions earlier in the drug development process.
Human Biological Samples (HBS) stored in biobanks facilitate researchers in identifying biomarkers and genetic factors thus shifting the industry to a personalized approach to medicine.
Biobanking for research will remain as the dominant sector. The growth of biobanking for therapeutic use will be driven by growing interest in stem cell treatment.
Download paper to find out more.